Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5783-5792

  Gerger, Armin ^a   El Khoueiry, Anthony ^a   Zhang, Wu ^a   Yang, Dongyun ^a   Singh, Harpreet ^a   Bohanes, Pierre ^a   Ning, Yan ^a   Winder, Thomas ^a   LaBonte, Melissa J ^a   Wilson, Peter M ^a   Benhaim, Leonor ^a   Paez, David ^a   El Khoueiry, Rita ^a   Absenger, Gudrun ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXALIPLATIN; SOMATOMEDIN C; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINES; COLORECTAL NEOPLASMS; CYTOKINES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENETIC VARIATION; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052426625     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1115     Document Type: Article

References (41)

1. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660 (Pubitemid 36749213)
3. Gerger A., Labonte M., Lenz H.J. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011;17:134-141
4. Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158-163
5. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009;29:789-791
6. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
7. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-1183
8. Cunningham D., Atkin W., Lenz H.J., Lynch H.T., Minsky B., Nordlinger B., et al. Colorectal cancer. Lancet 2010;375:1030-1047
9. Welch S., Spithoff K., Rumble R.B., Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: A systematic review. Ann Oncol 2010;21:1152-1162
10. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019
11. Steffensen K.D., Waldstrom M., Brandslund I., Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-116
12. Schultheis A.M., Lurje G., Rhodes K.E., Zhang W., Yang D., Garcia A.A., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-7563
13. Formica V., Palmirotta R., Del Monte G., Savonarola A., Ludovici G., De Marchis M.L., et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011;26:143-151
14. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678
15. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21-26
16. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741
17. Cao Y., Zhong W., Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009;19:338-343
18. Lee P.H., Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008;36:D820-D824 (Pubitemid 351149829)
19. Lee P.H., Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 2009;25:1048-1055
20. Conneely K.N., Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007;81:1158-1168 (Pubitemid 350211447)
21. Hayes D.F. Bevacizumab treatment for solid tumors: Boon or bust? JAMA 2011;305:506-508
22. Loupakis F., Cremolini C., Fioravanti A., Orlandi P., Salvatore L., Masi G., et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2010;104:1262-1269
23. Pander J., Wessels J.A., Gelderblom H., Van der Straaten T., Punt C.J., Guchelaar H.J. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 2011;22:1147-1153
24. Kim H.O., Jo Y.H., Lee J., Lee S.S., Yoon K.S. The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep 2008;20:1181-1187
25. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003;9:677-684 (Pubitemid 36749216)
26. Yang S.X., Steinberg S.M., Nguyen D., Wu T.D., Modrusan Z., Swain S.M. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 2008;14:5893-5899
27. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small-cell lung cancer treated with chemotherapy with or without Bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412 (Pubitemid 351413922)
28. Hansen T.F., Sørensen F.B., Spindler K.L., Olsen D.A., Andersen R.F., Lindebjerg J., et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010;456:251-260
29. Zeng Y., Sun H.R., Yu C., Lai Y., Liu X.J., Wu J., et al. CXCR1 and CXCR2 are novel mechano-sensors mediating laminar shear stress-induced endothelial cell migration. Cytokine 2011;53:42-51.
30. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992-997 (Pubitemid 41294446)
31. Cascone T., Herynk M.H., Xu L., Du Z., Kadara H., Nilsson M.B., et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011;121:1313-1328
32. Moriai T., Kobrin M.S., Hope C., Speck L., Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A 1994;91:10217-10221 (Pubitemid 24311980)
33. Lanuti M., Liu G., Goodwin J.M., Zhai R., Fuchs B.C., Asomaning K., et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14:3216-3222
34. Pander J., Gelderblom H., Antonini N.F., Tol J., Van Krieken J.H., Van der Straaten T., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010;46:1829-1834
35. Van Cruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-888 (Pubitemid 41688561)
36. Verheus M., McKay J.D., Kaaks R., Canzian F., Biessy C., Johansson M., et al. Common genetic variation in the IGF-1 gene, serum IGF-I levels, and breast density. Breast Cancer Res Treat 2008;112:109-122
37. Jiang Z.Y., He Z., King B.L., Kuroki T., Opland D.M., Suzuma K., et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003;278:31964-31971 (Pubitemid 37048384)
38. Zhao X., Dai W., Zhu H., Zhang Y., Cao L., Ye Q., et al. Epidermal growth factor (EGF) induces apoptosis in a transfected cell line expressing EGF receptor on its membrane. Cell Biol Int 2006;30:653-658 (Pubitemid 44209330)
39. Tikhomirov O., Carpenter G. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. J Biol Chem 2004;279:12988-12996 (Pubitemid 38445875)
40. Chiu B., Mirkin B., Madonna M.B. Mitogenic and apoptotic actions of epidermal growth factor on neuroblastoma cells are concentration-dependent. J Surg Res 2006;135:209-212 (Pubitemid 44414891)
41. Graziano F., Ruzzo A., Loupakis F., Canestrari E., Santini D., Catalano V., et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427-1434